What does CRMTS mean in FDA
CBER is the Center for Biologics Evaluation and Research, a division of the U.S. Food and Drug Administration (FDA). CBER is the FDA regulatory authority for all products derived from biotechnology, such as vaccines, blood and blood components, allergenic products, gene therapies, tissues and cellular therapies. The FDA's Regulatory Meetings Management Tracking System (CRMTS) enables CBER to monitor its activities related to regulatory meetings and associated activities.
CRMTS meaning in FDA in Governmental
CRMTS mostly used in an acronym FDA in Category Governmental that means CBER (Center for Biologics Evaluation and Research) Regulatory Meetings management Tracking System
Shorthand: CRMTS,
Full Form: CBER (Center for Biologics Evaluation and Research) Regulatory Meetings management Tracking System
For more information of "CBER (Center for Biologics Evaluation and Research) Regulatory Meetings management Tracking System", see the section below.
» Governmental » FDA
Essential Questions and Answers on CBER (Center for Biologics Evaluation and Research) Regulatory Meetings management Tracking System in "GOVERNMENTAL»FDA"
What is CBER?
CBER stands for the Center for Biologics Evaluation and Research, a division of the U.S. Food and Drug Administration (FDA).
What does CRMTS stand for?
CRMTS stands for Regulatory Meetings Management Tracking System.
What type of products are regulated by CBER?
CBER regulates products derived from biotechnology such as vaccines, blood and blood components, allergenic products, gene therapies, tissues and cellular therapies.
What is the purpose of CRMTS?
The purpose of CRMTS is to enable CBER to monitor its activities related to regulatory meetings and associated activities.
Who developed CRMTS?
CRMTS was developed by the U.S. Food and Drug Administration (FDA).
Final Words:
In summary, CBER stands for Center for Biologics Evaluation and Research and it is a division of the U.S. Food and Drug Administration (FDA). Regulatory Meetings Management Tracking System (CRMTS) was developed by FDA in order to monitor CBER's activities related to regulatory meetings and associated activities in regards to products derived from biotechnology such as vaccines, blood components etc.